ARTICLE | Clinical News
ATryn: Phase III started
August 4, 2014 7:00 AM UTC
LFB’s rEVO Biologics Inc. subsidiary began the double-blind, placebo-controlled, U.S. Phase III PRESERVE-1 trial to evaluate ATryn in about 120 pregnant women. Patients will receive an initial 250 mg ...